You are here

  • Home
  • Archive
  • Volume 73, Issue Suppl 2
  • OP0151 A Phase 2B, 24-Week Study of VX-509 (DECERNOTINIB), an Oral Selective Janus Kinase 3 Inhibitor, in Combination with Background Methotrexate in Rheumatoid Arthritis

Article metrics

Article menu
Download PDFPDF
EULAR 2014: Scientific Abstracts
Oral Presentations. Abstract session: RA - non biologic and small molecules
OP0151 A Phase 2B, 24-Week Study of VX-509 (DECERNOTINIB), an Oral Selective Janus Kinase 3 Inhibitor, in Combination with Background Methotrexate in Rheumatoid Arthritis

 

Online download statistics by month:

Online download statistics by month: June 2014 to March 2024

AbstractFullPdf
Jun 2014402
Jul 2014501
Aug 20141800
Sep 2014400
Oct 20141000
Nov 2014400
Dec 2014601
Jan 2015600
Feb 2015601
Mar 20151701
Apr 2015600
May 2015501
Jun 2015901
Jul 20151502
Aug 20151801
Sep 20152602
Oct 20151100
Nov 20152102
Dec 20152102
Jan 20161300
Feb 2016901
Mar 20161400
Apr 2016700
May 20161003
Jun 20161302
Jul 2016500
Aug 201648016
Sep 2016900
Oct 201615036
Nov 201614022
Dec 201617027
Jan 2017901
Feb 20171000
Mar 20171000
Apr 20171901
May 20171301
Jun 20171000
Jul 2017400
Aug 20172401
Sep 20171200
Oct 2017600
Nov 2017800
Dec 20172200
Jan 2018800
Feb 20181000
Mar 20181400
Apr 20182000
May 20181400
Jun 2018600
Jul 20182203
Aug 2018800
Sep 20181200
Oct 2018601
Nov 20181800
Dec 2018600
Jan 2019400
Feb 2019400
Mar 2019600
Apr 2019400
May 2019800
Jul 2019200
Aug 2019402
Oct 2019800
Nov 2019200
Dec 2019600
Jan 20201001
Feb 2020200
Mar 2020200
Apr 20201803
May 2020200
Jun 2020400
Jul 2020200
Sep 20201201
Oct 2020400
Nov 20202800
Dec 2020200
Jan 2021800
Mar 2021400
Apr 2021801
May 2021500
Jul 2021100
Oct 2021500
Nov 20211000
Dec 2021801
Feb 2022500
Mar 2022300
Apr 2022301
May 2022200
Jun 2022500
Jul 20221400
Aug 2022800
Sep 2022200
Oct 2022600
Nov 20221200
Dec 20221001
Jan 2023800
Feb 2023600
Mar 2023300
May 2023600
Jun 2023500
Jul 2023200
Aug 2023400
Sep 2023400
Dec 2023600
Jan 2024200
Feb 2024400
Mar 2024600
Total9860143